IMS Health, FMI to optimize targeting of precision therapies in oncology

Commercial, medical and outcomes research teams in biopharma and life sciences companies will now be able to leverage an offering that combines IMS Health’s powerful Real-World Evidence (RWE) platform providing clinical and cost-of-care insights with Foundation Medicine’s dynamic knowledgebase of comprehensive cancer genomic profiles, all at the patient-anonymous level.

Through the collaboration, IMS Health’s clients will gain unprecedented insights to rapidly assess health outcomes and effectiveness, and to improve cancer care by better connecting patients to the right targeted therapies at the right time.

"As life sciences companies look to deploy new, targeted therapies that address the unique molecular drivers of specific cancers, it has become increasingly important for them to better understand unmet needs, treatment decisions and outcomes for patient populations living with those cancers," said Jon Resnick, IMS Health vice president and general manager of Real-World Evidence Solutions.

"This collaboration with Foundation Medicine extends our Real-World Evidence platform – uniquely linking claims, EMR and biomarker data at the anonymous patient level to drive a complete understanding of the oncology patient journey and improve clinical development and commercialization strategies."

These enhanced oncologic insights will be powered by Evidence 360 and FoundationCORE. Evidence 360 is IMS Health’s scalable and secure RWE platform that helps clients extract, analyze and visualize real-world data to better understand and measure healthcare outcomes.

It brings together IMS Health’s vast library of patient-anonymous data with other patient-anonymous sources of health information to help life sciences companies interpret real-world outcomes and better target their commercial efforts. FoundationCORE is a molecular information knowledgebase containing comprehensive cancer genomic information and insights from more than 43,000 clinical cases profiled by Foundation Medicine.

FoundationCORE evolves in real-time, informed by every new cancer patient tested with the company’s commercial assays, FoundationOne and FoundationOne Heme.

"There is recognition within the healthcare industry that rich and highly credible information will be the primary catalyst for the broad adoption of precision medicine, particularly in oncology," said Michael J. Pellini, M.D., chief executive officer of Foundation Medicine.

"As the leader in molecular information solutions, Foundation Medicine’s collaboration with IMS Health expands existing relationships with our biopharma partners, further underscoring the value of FoundationCORE and its impact on informing physicians and patients, and transforming clinical practice."